Results 111 to 120 of about 5,616,277 (263)
How many readers understand the discussion on the statistics methodology? A plea for making things reader-friendly. [PDF]
Acta Obstet Gynecol ScandMatsubara S, Ishikawa S.
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec +6 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio +8 more
wiley +1 more source
Physical Therapy With Hippotherapy Affects Balance Control in the Elderly: A Critical Appraisal. [PDF]
Health Sci RepChu L, Zou J, Liu S, Hao J.
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Measuring performance in cancer services during COVID-19 and beyond: a novel case throughput metric using NHS Cancer Waiting Times data. [PDF]
J Public Health (Oxf)Lam CHM, Mason T, Hollingsworth B.
europepmc +1 more source